GASTICA SYRUP

Indications

• Gastrointestinal disorders
• Respiratory conditions
• Metabolic syndrome
• Diabetes
• Hyperlipidemia
• Inflammatory diseases

Dosage

Children: Refer to established guidelines or consult a healthcare professional for specific dosing recommendations.

Adults: Refer to established guidelines or consult a healthcare professional for specific dosing recommendations.

Mechanism of action

The active compounds in Aege, such as flavonoids and phenolic acids, exhibit their effects through multiple pathways. Flavonoids are known to modulate signaling pathways that regulate inflammation and oxidative stress. They also enhance the activity of endogenous antioxidant enzymes, thus reducing cellular damage. Additionally, Aege may influence glucose metabolism and lipid profiles, contributing to its benefits in metabolic disorders.

Pharmacodynamics

Aege demonstrates a range of pharmacodynamic effects, including anti-inflammatory actions by inhibiting pro-inflammatory cytokines, antioxidant effects through the scavenging of free radicals, and antimicrobial properties against various pathogens. Its ability to modulate metabolic processes contributes to improved insulin sensitivity and lipid metabolism, making it potentially beneficial in managing conditions like diabetes and hyperlipidemia.

Pharmacokinetics

The pharmacokinetics of Aege are not well-characterized in the literature. However, it is assumed that the active constituents are absorbed in the gastrointestinal tract, metabolized in the liver, and excreted via the urine and feces. The bioavailability and half-life of specific compounds may vary depending on the preparation and dosage form used.

Pregnancy

The safety of Aege during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether Aege is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Heartburn
• Dyspepsia
• Gastroesophageal reflux disease (GERD)
• Peptic ulcer disease

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines for paediatric patients, as dosing will depend on the child's age, weight, and specific indications.

Adults: Refer to the BNF for specific dosing recommendations for adults, as doses may vary based on the formulation and clinical condition being treated.

Mechanism of action

Alumina works by neutralizing gastric acid through a chemical reaction that forms aluminum chloride and water, thereby increasing the pH level in the stomach. This action alleviates symptoms associated with hyperacidity, such as heartburn and dyspepsia, by reducing the acidity of the stomach contents and promoting a more favorable environment for gastric mucosa.

Pharmacodynamics

Alumina exhibits its pharmacological effects primarily through its antacid properties. It binds to gastric acid in the stomach, leading to a decrease in acidity and helping to relieve discomfort from acid-related conditions. The effectiveness of alumina as an antacid is influenced by its ability to form complexes with hydrochloric acid, which decreases the overall acid concentration in the gastrointestinal tract.

Pharmacokinetics

Alumina is not significantly absorbed in the gastrointestinal tract, which limits its systemic effects. The pharmacokinetic profile indicates that alumina acts locally in the stomach and intestines, where it neutralizes acid without being absorbed into the bloodstream. The elimination of aluminum from the body occurs primarily through the kidneys, and when used as directed, it typically does not lead to toxicity.

Pregnancy

Safety in pregnancy has not been established. Use only if clearly needed and the potential benefits outweigh the risks.

Breast-feeding

Safety during breastfeeding is not established. Caution is advised.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Powder
• Suspension

Indications

• Calcium deficiency
• Osteoporosis prevention and treatment
• Hypoparathyroidism
• Rickets
• Acid indigestion
• Heartburn

Dosage

Adults: For calcium supplementation, the typical adult dose is 1,000 to 1,200 mg of elemental calcium per day, divided into two or three doses. For use as an antacid, 500 to 1

Mechanism of action

Calcarea primarily acts by supplementing calcium levels in the body, which is vital for several biological processes. Calcium ions are essential for the normal functioning of muscles and nerves and play a pivotal role in blood coagulation. In the gastrointestinal tract, calcium carbonate acts as an antacid by neutralizing stomach acid, thus providing relief from symptoms of heartburn and indigestion. The mechanism involves the reaction of calcium carbonate with hydrochloric acid in the stomach to form calcium chloride, water, and carbon dioxide.

Pharmacodynamics

The pharmacodynamic effects of calcarea are largely related to its calcium content. Through its role in maintaining calcium homeostasis, it supports bone mineralization, prevents bone resorption, and contributes to the overall health of the skeletal system. Additionally, by acting as an antacid, it alleviates symptoms of gastric acidity and promotes comfort in patients suffering from gastroesophageal reflux disease (GERD) and peptic ulcer disease.

Pharmacokinetics

Calcarea is absorbed in the gastrointestinal tract, with absorption being influenced by factors such as the presence of food and the pH of the stomach. Peak plasma concentrations of calcium usually occur within 1 to 4 hours after ingestion. The bioavailability of calcium carbonate can vary, but it is generally higher when taken with meals. Calcium is primarily excreted by the kidneys, with a small amount excreted in the feces. The half-life of calcium in the body is not well defined due to its extensive physiological roles and regulatory mechanisms.

Pregnancy

Calcarea is often considered safe during pregnancy; however, clinical evidence is limited. Consultation with a healthcare provider is recommended.

Breast-feeding

It is generally deemed safe to use Calcarea while breastfeeding, but caution is advised and it is best to consult a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Sterilization of medical equipment
• Food preservation
• Germicidal applications in various industrial processes

Dosage

Children: Refer to specific guidelines for industrial and clinical applications as

Adults: Refer to specific guidelines for industrial and clinical applications as dosing varies widely based on the use case and concentrations employed.

Mechanism of action

Supercritical carbon dioxide demonstrates its germicidal effect primarily by interfering with microbial protein synthesis. It is hypothesized that in its supercritical state, CO2 competes with Met-tRNA(fMet), leading to a decrease in the formation of formyl-methionyl-tRNA (fMet-tRNA(fMet)), a crucial component in prokaryotic protein synthesis. The formation of a stable carbamoyl-methionyl-tRNA (cMet-tRNA(fMet)) complex with translational initiation factor 2 (GTP-IF2) results in an inactive preinitiation complex that cannot synthesize proteins, ultimately causing microbial cell death due to inhibited protein synthesis and energy depletion.

Pharmacodynamics

While specific pharmacodynamic data for carbonica are lacking, its primary action as a germicide indicates a capacity to disrupt biological processes in microbial cells, particularly by inhibiting protein synthesis. This inhibition leads to cell death, which is the basis for its application in sterilization processes.

Pharmacokinetics

Details on the pharmacokinetics of carbonica are not specifically provided; however, its gaseous nature suggests that it can rapidly diffuse through biological membranes. In clinical and industrial settings, the absorption and distribution of CO2 would depend on the concentration and the physical state (gas vs. supercritical) employed. The elimination of CO2 from the body is primarily through respiration, as it is a natural byproduct of cellular metabolism.

Pregnancy

Data not found. Consult relevant guidelines or literature for safety information during pregnancy.

Breast-feeding

Data not found. Consult relevant guidelines or literature for safety information during breastfeeding.

Storage

Store in a cool, dry place, away from direct sunlight and sources of ignition.

Formulations

• Supercritical carbon dioxide

Indications

• Digestive disorders
• Inflammation
• Wound healing
• Nutritional support
• Antioxidant support

Dosage

Children: Refer to established guidelines for dietary intake or consult a healthcare provider for specific therapeutic uses.

Adults: Refer to established guidelines for dietary intake or consult a healthcare provider for specific therapeutic uses.

Mechanism of action

Papain, the primary enzyme in carica, acts as a protease, facilitating the hydrolysis of peptide bonds in proteins. This enzymatic activity aids in digestion by breaking down proteins into more easily absorbed amino acids and peptides. Additionally, the antioxidants in carica may help reduce oxidative stress, thereby exhibiting anti-inflammatory effects.

Pharmacodynamics

The pharmacodynamic effects of carica largely stem from its enzymatic activity and antioxidant properties. Papain enhances protein digestion, improving nutrient absorption. The antioxidants present in carica, such as vitamin C, help neutralize free radicals, potentially reducing inflammation and promoting overall health. The anti-inflammatory effects may also be beneficial in managing conditions associated with inflammation.

Pharmacokinetics

The pharmacokinetics of carica are not well defined in clinical literature, as it is primarily consumed as a food source rather than a pharmaceutical product. However, the absorption of nutrients and enzymes from carica can vary based on the individual's digestive health. The bioavailability of papain may be influenced by factors such as gastric pH, presence of other food substances, and individual metabolic rates.

Pregnancy

There is insufficient reliable information regarding the safety of carica during pregnancy, so it is advisable to avoid use unless directed by a healthcare professional.

Breast-feeding

Due to a lack of adequate studies, the safety of carica during breastfeeding is not well established. Consultation with a healthcare provider is recommended.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Digestive disorders
• Liver disorders
• Appetite stimulation
• Anti-inflammatory conditions
• Antidiabetic effects

Dosage

Children: Refer to established herbal guidelines, as specific dosing may vary based on preparation and intended use.

Adults: Refer to established herbal guidelines, as specific dosing may vary based on preparation and intended use.

Mechanism of action

Chirata exhibits its pharmacological effects through various mechanisms, including the modulation of glucose metabolism, enhancement of insulin sensitivity, and promotion of liver function. The active compound swertiamarin may act on multiple pathways, influencing cellular signaling related to glucose uptake and lipid metabolism, and exhibiting anti-inflammatory effects by inhibiting pro-inflammatory cytokines.

Pharmacodynamics

The pharmacodynamics of chirata involves its interaction with multiple biochemical pathways. The bitter compounds stimulate the secretion of digestive enzymes, enhancing gut health and improving appetite. Additionally, chirata's anti-inflammatory properties may help in reducing oxidative stress and protecting against cellular damage. It has been shown to possess hepatoprotective effects, which can aid in the detoxification processes of the liver.

Pharmacokinetics

Chirata is primarily administered orally, and its active compounds are absorbed in the gastrointestinal tract. The pharmacokinetics, including absorption, distribution, metabolism, and excretion, can vary based on the formulation and preparation method. Preliminary studies suggest that the bioavailability of swertiamarin may be influenced by its solubility and the presence of other constituents in the herbal preparation. Further research is needed to fully elucidate its pharmacokinetic profile.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Loss of appetite
• Headache
• Dizziness

Interactions

• May enhance the effects of anticoagulants
• Potential interaction with antidiabetic medications

Precautions

• Use with caution in patients with liver or kidney disease
• Monitor blood glucose levels in diabetic patients

Pregnancy

Limited data on safety during pregnancy. Use only if clearly needed.

Breast-feeding

Limited data on excretion in breast milk. Exercise caution.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Dried whole plant
• Powdered extract
• Tinctures

Indications

• Malaria (treatment and prevention)
• Muscle cramps
• Certain types of arrhythmias (off-label use)

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines.

Adults: Refer to prescribing guidelines, as dosing can vary based on the formulation and specific clinical scenario.

Mechanism of action

Quinine, the primary active compound derived from cinchona, works by interfering with the parasite's ability to digest hemoglobin in red blood cells. It inhibits the parasite's metabolism and reproduction, leading to a reduction in malaria symptoms. Additionally, quinine has effects on the neuromuscular system, leading to muscle relaxation.

Pharmacodynamics

Quinine exhibits antipyretic, analgesic, and anti-inflammatory properties. Its analgesic effects are attributed to its action on both peripheral and central nervous systems. The drug alters the conduction of nerve impulses and reduces fever by acting on the hypothalamic heat-regulating center.

Pharmacokinetics

Quinine is well-absorbed after oral administration, with peak plasma concentrations occurring within 1 to 3 hours. It is extensively metabolized in the liver, primarily through cytochrome P450 enzymes, and has a half-life of about 10 hours. Quinine is eliminated through urine, with both unchanged drug and metabolites being excreted.

Contra-indications

• Hypersensitivity to cinchona alkaloids
• History of cinchona-induced thrombocytopenia
• Severe renal impairment

Adverse effects

• Nausea
• Vomiting
• Tinnitus
• Headache
• Visual disturbances
• Allergic reactions
• Cinchonism (a syndrome that includes symptoms like tinnitus, headache, dizziness, and nausea)

Interactions

• May enhance the effects of anticoagulants such as warfarin
• Potentially interacts with other antimalarial agents
• May decrease the effectiveness of certain antihypertensive medications

Precautions

• Use with caution in patients with a history of arrhythmias
• Monitor for signs of cinchonism, particularly at higher doses
• Caution in patients with liver or renal impairment

Pregnancy

Cinchona is generally not recommended during pregnancy due to potential risks to the fetus, including teratogenic effects.

Breast-feeding

Cinchona may be excreted in breast milk; caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

• Cinchona bark (powder or extract)
• Quinine (derived from cinchona for therapeutic use)

Indications

• Digestive disorders
• Inflammation
• Antimicrobial infections
• Antioxidant support

Dosage

Children: Specific dosing information is not available; refer to established guidelines and clinical recommendations for appropriate dosing.

Adults: Specific dosing information is not available; refer to established guidelines and clinical recommendations for appropriate dosing.

Mechanism of action

Embelin, the main active compound in Embelia ribes, exhibits its pharmacological effects by acting as a potent inhibitor of certain enzymes, including lipoxygenase and cyclooxygenase. These actions may lead to reduced production of pro-inflammatory mediators, thus contributing to its anti-inflammatory effects. Additionally, embelin has been shown to possess antioxidant properties, which may help mitigate oxidative stress in cells.

Pharmacodynamics

The pharmacodynamics of embelia are primarily related to its ability to modulate inflammatory pathways and reduce oxidative stress. It has been observed to exert an inhibitory effect on various inflammatory mediators, which may help alleviate symptoms associated with inflammation. Furthermore, embelia's antimicrobial activity has been attributed to its ability to disrupt microbial cell membranes and inhibit the growth of pathogenic microorganisms.

Pharmacokinetics

The pharmacokinetics of embelia, especially regarding its absorption, distribution, metabolism, and excretion, are not well-documented in the literature. However, it is known that compounds like embelin may undergo hepatic metabolism and exhibit variable bioavailability depending on the formulation and route of administration. Further studies are needed to fully elucidate the pharmacokinetic profile of embelia and its active constituents.

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Allergic reactions

Precautions

• Use with caution in patients with gastrointestinal disorders.
• Monitor for potential allergic reactions, especially in sensitive individuals.

Pregnancy

Insufficient reliable information is available regarding the safety of embelia during pregnancy. Caution is advised.

Breast-feeding

Limited information is available. It is recommended to consult a healthcare provider before use while breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Powdered extract
• Capsules
• Tinctures

Indications

• Loss of appetite
• Indigestion
• Dyspepsia
• Gastritis
• Biliary disorders

Dosage

Children: Refer to established pediatric guidelines or consult a healthcare provider for specific dosing information as there is no standard dosing regimen.

Adults: Refer to established herbal guidelines or consult a healthcare provider for specific dosing information as there is no standard dosing regimen.

Mechanism of action

The bitter compounds found in gentian, such as gentiopicroside and amarogentin, stimulate the taste receptors in the mouth, activating the hypothalamus and increasing the secretion of digestive juices, including saliva, gastric acid, and bile. This enhances the digestive process and improves appetite.

Pharmacodynamics

Gentiana exhibits a range of pharmacological activities, primarily due to its bitter constituents. The activation of bitter taste receptors leads to increased gastrointestinal motility and improved digestion. Additionally, gentian may possess mild anti-inflammatory and antioxidant properties, contributing to its overall health benefits.

Pharmacokinetics

The pharmacokinetics of gentian compounds have not been extensively studied. However, it is believed that the bitter principles are absorbed in the gastrointestinal tract and exert their effects locally and systemically. The metabolism and excretion pathways remain largely undefined in clinical literature, requiring further research for comprehensive understanding.

Pregnancy

There is insufficient data on the safety of gentiana during pregnancy. It is advisable to avoid use unless prescribed by a healthcare provider.

Breast-feeding

Due to a lack of data on the excretion of gentiana in breast milk, it is recommended to consult a healthcare professional before use while breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Inflammatory conditions
• Oxidative stress-related diseases
• Cancer prevention and treatment
• Neuroprotection

Dosage

Children: Refer to specific guidelines or clinical studies for precise dosing, as no standard dosage is established.

Adults: Refer to specific guidelines or clinical studies for precise dosing, as no standard dosage is established.

Mechanism of action

Luteolin exerts its effects primarily through the inhibition of pro-inflammatory cytokines and enzymes involved in inflammation, such as COX-2 and lipoxygenase. It also acts as a potent antioxidant by scavenging free radicals and chelating metal ions, which helps reduce oxidative stress. Additionally, luteolin can modulate the activity of several signaling pathways, including NF-kB and MAPK pathways, which play critical roles in cell survival, proliferation, and inflammatory responses.

Pharmacodynamics

Luteolin exhibits a range of pharmacological effects, including anti-inflammatory, antioxidant, and anticancer activities. Its anti-inflammatory effects are mediated by the suppression of inflammatory mediators and cytokines. The antioxidant properties help protect cells from oxidative damage, which is implicated in various chronic diseases. Moreover, luteolin has shown potential in inhibiting cancer cell growth and inducing apoptosis in various cancer types, including breast and prostate cancers.

Pharmacokinetics

Luteolin is absorbed in the gastrointestinal tract and undergoes extensive metabolism. It has a relatively low bioavailability due to its rapid conjugation and elimination. The major metabolic pathways include glucuronidation and sulfation. The elimination half-life of luteolin varies depending on the dosage form and individual metabolism. Distribution studies indicate that luteolin can cross the blood-brain barrier, which may contribute to its neuroprotective effects.

Pregnancy

There is insufficient data on the use of lutea during pregnancy. It is recommended to avoid unless the benefits outweigh the risks.

Breast-feeding

Data on the excretion of lutea in human milk is not available. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Constipation
• Indigestion
• Heartburn

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Milk of Magnesia acts as an osmotic laxative by drawing water into the intestines, which distends the bowel and stimulates peristalsis. Additionally, magnesium supplements can reduce platelet aggregation by inhibiting calcium influx, a key factor in platelet aggregation.

Pharmacodynamics

The osmotic effect of magnesium hydroxide increases the water content in the intestinal lumen, leading to softer stools and promoting bowel movements. This laxative effect is primarily due to its ability to retain fluid, thereby enhancing colonic motility. The reduction of platelet aggregation is mediated through modulation of calcium levels within platelets.

Pharmacokinetics

Magnesium hydroxide is not significantly absorbed in the gastrointestinal tract, and its laxative effect is local within the intestine. The onset of action typically occurs within 30 minutes to 6 hours after oral administration. Excretion of magnesium occurs primarily through the kidneys, and elevated magnesium levels can occur in patients with renal impairment.

Adverse effects

• Diarrhea
• Abdominal cramping
• Electrolyte imbalance
• Nausea

Precautions

• Use with caution in patients with renal impairment
• Avoid prolonged use to prevent dependence
• Monitor for signs of dehydration

Pregnancy

Magnesium hydroxide is generally considered safe during pregnancy, but should be used under medical supervision.

Breast-feeding

Magnesium hydroxide is excreted in breast milk, but is unlikely to affect the nursing infant when used in recommended doses.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• Oral suspension
• Tablet

Indications

• Gastrointestinal disorders
• Diarrhea
• Dysentery
• Respiratory conditions
• Inflammatory conditions
• Antimicrobial therapy

Dosage

Children: Refer to herbal medicine guidelines or a qualified healthcare provider for appropriate dosing.

Adults: Refer to herbal medicine guidelines or a qualified healthcare provider for appropriate dosing.

Mechanism of action

The active constituents of marmelos, such as flavonoids and tannins, exhibit various pharmacological activities. These compounds are believed to exert anti-inflammatory effects by inhibiting pro-inflammatory mediators and enhancing antioxidant defense mechanisms. Additionally, marmelos may promote digestive health by stimulating gastric secretions and exhibiting antimicrobial properties against gastrointestinal pathogens.

Pharmacodynamics

Marmelos has been shown to modulate various biochemical pathways, including the inhibition of cyclooxygenase enzymes, leading to reduced prostaglandin synthesis and inflammation. Its antioxidant properties help combat oxidative stress, which is implicated in chronic diseases. Furthermore, the antimicrobial activity of marmelos may aid in protecting against infections, particularly in the gastrointestinal tract.

Pharmacokinetics

The pharmacokinetics of marmelos have not been extensively studied in clinical settings. However, it is known that the bioactive compounds are absorbed in the gastrointestinal tract, where they exert their effects. The metabolism and excretion pathways are not well defined, necessitating further research to clarify these aspects.

Pregnancy

There is insufficient reliable information regarding the safety of marmelos during pregnancy. It is advisable to consult a healthcare professional before use.

Breast-feeding

Due to limited data on the excretion of marmelos in breast milk, caution is recommended. It is best to consult a healthcare provider before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Anxiety
• Sleep disorders
• Stress relief
• Mild depression
• Digestive issues

Dosage

Children: Dosage for paediatric patients should be determined by a qualified healthcare provider familiar

Adults: Dosage varies widely depending on the specific officinalis species and preparation. General guidance for herbal preparations should be followed, and consulting a healthcare professional is recommended.

Mechanism of action

The mechanism of action of officinalis species varies depending on the specific plant. For example, Melissa officinalis is thought to exert its effects primarily through modulation of GABA (gamma-aminobutyric acid) receptors, which are crucial for inhibitory neurotransmission in the brain. This interaction can lead to a calming effect, reducing anxiety and promoting sleep. Valeriana officinalis is believed to enhance GABAergic activity, potentially increasing GABA concentrations in the synaptic cleft, further contributing to its sedative properties.

Pharmacodynamics

Pharmacodynamics of officinalis species involve their effects on the central nervous system. The herbs are known to promote relaxation, reduce anxiety, and improve sleep quality. Their bioactive compounds, such as flavonoids and essential oils, are thought to influence neurotransmitter systems, particularly GABA, which plays a key role in anxiety regulation. Additionally, these plants may exhibit antioxidant properties, contributing to overall health benefits.

Pharmacokinetics

Pharmacokinetics of officinalis species can vary widely based on the specific plant and its preparation. Generally, the active components are absorbed in the gastrointestinal tract after ingestion. The onset of action can occur within 30 minutes to several hours, depending on the formulation. Metabolism occurs primarily in the liver, with elimination through urine. The half-life of the active compounds may vary, necessitating multiple doses for sustained effects.

Pregnancy

Consult healthcare provider before use. Limited data on safety in pregnancy.

Breast-feeding

Consult healthcare provider before use. Limited data on safety while breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Digestive disorders
• Inflammation
• Constipation
• Nutritional support
• Immune system support

Dosage

Children: Refer to established dietary guidelines or consult a healthcare professional for specific recommendations.

Adults: Refer to established dietary guidelines or consult a healthcare professional for specific recommendations.

Mechanism of action

The primary active components of papaya include papain and other proteolytic enzymes, which facilitate the digestion of proteins in the gastrointestinal tract. Papain acts by cleaving peptide bonds in proteins, leading to their breakdown into smaller peptides and amino acids. This enzymatic activity can aid in improving nutrient absorption and reducing symptoms of digestive discomfort.

Pharmacodynamics

Papaya exhibits anti-inflammatory and antioxidant properties, attributed to its high levels of vitamins A, C, and E, as well as flavonoids and carotenoids. These compounds help neutralize free radicals in the body, potentially reducing oxidative stress and inflammation. Additionally, papaya's enzymatic activity may help alleviate bloating and constipation, enhancing overall gastrointestinal health.

Pharmacokinetics

The bioavailability of papaya's active compounds varies depending on the preparation and method of consumption. When consumed as a whole fruit, the digestion and absorption of its components occur in the gastrointestinal tract. The enzymes like papain are generally stable in the acidic environment of the stomach, allowing for effective protein digestion. However, the precise pharmacokinetic parameters of papaya's components are not well-established in the literature.

Adverse effects

• Allergic reactions
• Gastrointestinal disturbances
• Skin rashes

Interactions

• May interact with anticoagulants and antiplatelet drugs
• Potential interaction with certain antihypertensive medications

Precautions

• Use with caution in individuals with known allergies to papaya or related plants
• Caution in patients with diabetes due to potential effects on blood sugar levels

Pregnancy

Papaya is generally considered safe in moderate amounts, but unripe papaya should be avoided due to potential effects on uterine contractions.

Breast-feeding

Limited information is available, but small amounts of ripe papaya are likely safe during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• Fresh fruit
• Dried fruit
• Papaya enzyme supplements

Indications

• Used as a thickening agent in pharmaceutical formulations
• Emulsifier in food products and dietary supplements
• Stabilizer in various topical and oral medications

Dosage

Children: Pediatric dosage is also dependent on the formulation and indication. Consult the specific product guidelines and refer to pediatric dosing recommendations.

Adults: Dosage varies depending on the specific formulation and indication. Refer to the specific product guidelines for appropriate dosing information.

Mechanism of action

Pseudocacia works primarily by forming a gel-like structure when hydrated, which increases the viscosity of the solution. This property allows it to stabilize emulsions and suspensions, thereby preventing the separation of ingredients in pharmaceutical formulations. The polysaccharide chains interact with water molecules, leading to the formation of a thickened gel matrix, which can also aid in drug delivery by controlling the release of active pharmaceutical ingredients.

Pharmacodynamics

Pseudocacia exhibits its pharmacodynamic effects through its thickening and stabilizing properties, which can enhance the bioavailability of certain drugs by controlling their release in the gastrointestinal tract. It may also contribute to the overall palatability of formulations by improving mouthfeel and texture. Additionally, it can help in masking the taste of bitter medications, making them easier to administer, particularly in pediatric formulations.

Pharmacokinetics

Pseudocacia is not absorbed in the gastrointestinal tract; rather, it acts locally within the digestive system. Its gel-forming ability allows it to retain water and form a viscous solution that can potentially slow gastric emptying and modulate the absorption of other substances. The excretion of pseudocacia occurs primarily through feces, as it is not metabolized by the body.

Pregnancy

There are no well-controlled studies of pseudocacia in pregnant women. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether pseudocacia is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Respiratory issues
• Digestive disorders
• Diuretic
• Anti-inflammatory

Dosage

Children: Refer to established guidelines for specific dosing, as paediatric doses must be carefully considered based on age, weight, and clinical condition.

Adults: Refer to established guidelines for specific dosing, as doses may vary based on formulation and condition treated.

Mechanism of action

The exact mechanism of action of robinia is not fully elucidated. However, it is believed that the active compounds, such as flavonoids and alkaloids, may exert their effects through antioxidant activity, anti-inflammatory properties, and modulation of gut microbiota. These actions could contribute to its use in traditional medicine for enhancing respiratory health and digestive function.

Pharmacodynamics

Robinia exhibits various pharmacodynamic properties, including anti-inflammatory and antioxidant effects. The flavonoids present in robinia may help reduce oxidative stress and inflammation, which can be beneficial in conditions related to these processes. Additionally, its potential diuretic effects may assist in fluid regulation and blood pressure control.

Pharmacokinetics

The pharmacokinetics of robinia, including absorption, distribution, metabolism, and excretion, are not well-characterized due to a lack of extensive clinical studies. It is assumed that the active compounds are absorbed through the gastrointestinal tract, but specific data on bioavailability, half-life, and elimination routes remain insufficient.

Pregnancy

Robinia has not been extensively studied in pregnant women. Caution is advised when administering during pregnancy due to potential risks.

Breast-feeding

Robinia is not well-studied in breastfeeding mothers. Caution is recommended due to the lack of data on excretion in breast milk.

Storage

Store in a cool, dry place away from direct sunlight. Ensure the container is tightly sealed.

Indications

• Stimulation of appetite
• Enhancement of vitality
• Potential use in specific cases of muscle weakness (historically)

Dosage

Children: For pediatric dosing, consult the BNF for Children, as appropriate dosing must be determined based on age and weight.

Adults: For specific dosing, refer to professional resources or clinical guidelines, as doses can vary based on the indication and formulation.

Mechanism of action

The primary active component, strychnine, acts as a competitive antagonist at glycine receptors in the spinal cord and brainstem. By inhibiting inhibitory neurotransmission (glycinergic signaling), strychnine leads to increased neuronal excitability and can cause hyperreflexia and convulsions. The mechanism results in heightened motor activity and can be life-threatening due to the potential for respiratory failure.

Pharmacodynamics

Strychnine exhibits a narrow therapeutic index, meaning that small increases in dose can lead to significant toxicity. Its effects can manifest as increased muscle tone, spasms, and hyperactivity. In toxic doses, it can cause generalized muscle contractions and can affect autonomic functions, leading to complications such as respiratory distress and cardiovascular instability.

Pharmacokinetics

Strychnine is rapidly absorbed from the gastrointestinal tract and has a volume of distribution that indicates extensive tissue binding. It undergoes hepatic metabolism and is primarily excreted in the urine. The half-life of strychnine ranges from 9 to 12 hours, but this can vary significantly based on individual metabolic factors. The onset of action occurs within 15 to 30 minutes after ingestion, with peak effects observed within a few hours.

Pregnancy

Vomica is not recommended during pregnancy due to potential risks and lack of safety data.

Breast-feeding

It is advised to avoid using vomica while breastfeeding due to insufficient safety information.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Mechanism of action

... Six 8 wk old female Swiss Webster mice were fed for 10 weeks purified diets containing 100 (control), 500 or 1000 ug aluminum/g diet. Brain and liver lipid peroxidation was determined by evaluating the production of 2-thiobarbituric acid reactive substances in brain and liver homogenates in the presence or absence of 50 uM ferrous iron. 2-Thiobarbituric acid reactive substances production in the absence of iron in brain homogenates from mice fed the 1000 ... ug/g diet was higher (30%) than that in the ... control group (3.1 vs 2.4 nmol 2-thiobarbituric acid reactive substances/mg protein). The addition of ferrous iron increased 2-thiobarbituric acid reactive substances production in brain homogenates from all 3 dietary groups. The iron induced 2-thiobarbituric acid reactive substances production was 26% higher in the 1000 ... ug/g /group/ brain homogenates than in the ... /control/ group (4.9 vs 3.9 nmol 2-thiobarbituric acid reactive subtances/mg protein). Brain 2-thiobarbituric acid reactive substances production in the presence and absence of iron was similar between the 100 and 500 ... ug/g /diet/ groups. 2-Thiobarbituric acid reactive substances production in liver homogenates measured either with or without iron was similar for the 3 groups. These results show that, in mice, dietary aluminum intoxication leads to increased brain 2-thiobarbituric acid reactive substance production, suggesting that enhanced lipid peroxidation may be one possible mechanism underlying the neurological damage associated with increased tissue aluminum. /Aluminum/ Evidence is presented indicating that dementias are associated with a relative insufficiency of magnesium in the brain. Such insufficiency may be attributable to low intake or retention of magnesium; high intake of a neurotoxic metal, such a aluminum, which inhibits activity of magnesium requiring enzymes; or impaired transport of magnesium and/or enhanced transport of the neurotoxic metal into brain tissue. It is proposed that Alzheimer's disease involves a defective transport process, characterized by both an abnormally high incorporation of aluminum and an abnormally low incorporation of magnesium into brain neurons. The hypothesis has advanced that an altered serum protein contributes to the progression of Alzheimer's disease by having a greater affinity for aluminum than for magnesium, in contrast to the normal protein, which binds magnesium better than aluminum. The altered protein crosses the blood-brain barrier more efficiently than the normal protein and competes with the normal protein in binding to brain neurons. Binding of the altered protein to the target neurons would both facilitate aluminum uptake and impede magnesium uptake. Evidence suggests that albumin is the serum protein that is altered. /Aluminum/ Aluminum is established as a neurotoxin, although the basis for its toxicity is unknown. It recently has been shown to alter the function of the blood brain barrier, which regulates exchanges between the central nervous system and peripheral circulation. The blood brain barrier owes its unique properties to the integrity of cell membranes that comprise it. Aluminum affects some of the membrane-like functions of the blood brain barrier. It increases the rate of transmembrane diffusion and selectively changes saturable transport systems without disrupting the integrity of the membranes or altering CNS hemodynamics. Such alterations in the access to the brain of nutrients, hormones, toxins, and drugs could be the basis of CNS dysfunction. Aluminum is capable of altering membrane function at the blood-brain barrier; many of its effects on the CNS as well as peripheral tissues can be explained by its actions as a membrane toxin. /Aluminum/ Chronic, oral administration of aluminum to rats increases the in vivo concentration of cyclic AMP and the phosphorylation of microtubule-associated protein-2 and the 200 kd neurofilament subunit. In the present study, the effect of t

Mechanism of action

Data not found. Supercritical carbon dioxide possesses germicide (bactericide and sporicide) effect. Despite of the fact, that this effect is used in industrial sterilization processes, the sterilization mechanism at molecular level is unclear. Our hypotheses can provide a molecular-biological explanation for the phenomenon. We believe that in supercritical state CO(2) reacts competitively with Met-tRNA(fMet), the formation rate and the amount of formyl-methionyl-tRNA (fMet-tRNA(fMet)) will be diminished by irreversible substrate consumption. The fMet-tRNA(fMet) possesses a key role in prokaryotic protein synthesis, being almost exclusively the initiator aminoacyl-tRNA. The formed carbamoyl-methionyl-tRNA (cMet-tRNA(fMet)), probably stable only under pressure and high CO(2) concentration, is stabilized by forming a ternary molecular complex with the GTP-form of the translational initiation factor 2 (GTP-IF2). This complex is unable to dissociate from preinitiation 70S ribosomal complex because of strong polar binding between the protein C-2 domain and the modified initiator aminoacyl-tRNA. The IF2-fMet-tRNA(fMet)-blocked 70S ribosomal preinitiation complex does not decompose following the GTP hydrolysis, becoming unable to synthesize proteins. The death of the microbial cell is caused by inhibition of the protein synthesis and energetic depletion. Moreover, we propose a possible mechanism for the accumulation of cMet-tRNA(fMet) in the bacterial cell. Since the translational process is an important target for antibiotics, the proposed mechanism could be a work hypothesis for discovery of new antibiotics. Made by high conservative character of prokaryotic translation initiation, the proposed IF2 pathway deterioration strategy may conduct to obtaining selective (with low mammalian toxicity) antimicrobials and at the same time, with reduced possibility of the drug resistance development. ... Well fed C. elegans (roundworm) avoid CO2 levels above 0.5%. Animals can respond to both absolute CO2 concentrations and changes in CO2 levels within seconds. Responses to CO2 do not reflect avoidance of acid pH but appear to define a new sensory response. Sensation of CO2 is promoted by the cGMP-gated ion channel subunits TAX-2 and TAX-4, but other pathways are also important. Robust CO2 avoidance in well fed animals requires inhibition of the DAF-16 forkhead transcription factor by the insulin-like receptor DAF-2. Starvation, which activates DAF-16, strongly suppresses CO2 avoidance. Exposure to hypoxia (<1% O2) also suppresses CO2 avoidance via activation of the hypoxia-inducible transcription factor HIF-1. The npr-1 215V allele of the naturally polymorphic neuropeptide receptor npr-1, besides inhibiting avoidance of high ambient O2 in feeding C. elegans, also promotes avoidance of high CO2. C. elegans integrates competing O2 and CO2 sensory inputs so that one response dominates. Food and allelic variation at NPR-1 regulate which response prevails. These results suggest that multiple sensory inputs are coordinated by C. elegans to generate different coherent foraging strategies. ... Adult Caenorhabditis elegans (roundworm) display an acute avoidance response upon exposure to CO2 that is characterized by the cessation of forward movement and the rapid initiation of backward movement. This response is mediated by a cGMP signaling pathway that includes the cGMP-gated heteromeric channel TAX-2/TAX-4. CO2 avoidance is modulated by multiple signaling molecules, including the neuropeptide Y receptor NPR-1 and the calcineurin subunits TAX-6 and CNB-1. Nutritional status also modulates CO2 responsiveness via the insulin and TGFbeta signaling pathways. CO2 response is mediated by a neural circuit that includes the BAG neurons, a pair of sensory neurons of previously unknown function. TAX-2/TAX-4 function in the BAG neurons to mediate acute CO2 avoidance. ... C. elegans senses and responds to CO2 using multiple signaling pathways and a neural network

Pharmacodynamics

Data not found.

Mechanism of action

The term "Milk of Magnesia" was first used to describe a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. Milk of magnesia is primarily used to alleviate constipation, but can also be used to relieve indigestion and heartburn. When taken internally by mouth as a laxative, the osmotic force of the magnesia suspension acts to draw fluids from the body and to retain those already within the lumen of the intestine, serving to distend the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents. Magnesium supplements have also been shown to reduce platelet aggregation by inhibiting in the influx of calcium, a crucial component of platelet aggregation.